Literature DB >> 21723839

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Christian Thoma1, Christopher P Day, Michael I Trenell.   

Abstract

Non-alcoholic fatty liver disease is a serious and growing clinical problem. Despite lifestyle modification, i.e. diet and physical activity, being the recommended therapy, there are currently no systematic evaluations of its efficacy. This review applies a systematic approach to evaluating lifestyle modifications studied to date. Medline (Pubmed), Scopus, and the Cochrane Controlled Trials Register were searched for studies and study groups assessing the effect of diet, physical activity, and/or exercise modification in adult populations with non-alcoholic fatty liver disease. The outcome markers of interest were indicators of steatosis, histological evidence of inflammation and fibrosis, and glucose control/insulin sensitivity. We identified 23 studies for inclusion; seven had control groups, but only six were randomised. Eleven groups received diet-only interventions, two exercise-only, and 19 diet and physical activity/exercise. Studies consistently showed reductions in liver fat and/or liver aminotransferase concentration, with the strongest correlation being with weight reduction. Of the 5 studies reporting changes in histopathology, all showed a trend towards reduction in inflammation, in 2 this was statistically significant. Changes in fibrosis were less consistent with only one study showing a significant reduction. The majority of studies also reported improvements in glucose control/insulin sensitivity following intervention. However, study design, definition of disease, assessment methods, and interventions varied considerably across studies. Lifestyle modifications leading to weight reduction and/or increased physical activity consistently reduced liver fat and improved glucose control/insulin sensitivity. Limited data also suggest that lifestyle interventions may hold benefits for histopathology. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21723839     DOI: 10.1016/j.jhep.2011.06.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  156 in total

1.  Morphofunctional Changes After Sleeve Gastrectomy and Very Low Calorie Diet in an Animal Model of Non-Alcoholic Fatty Liver Disease.

Authors:  Eider Talavera-Urquijo; Sarai Rodríguez-Navarro; Marc Beisani; Maria Teresa Salcedo-Allende; Aisha Chakkur; Marc Arús-Avilés; Manel Cremades; Salvador Augustin; María Martell; José M Balibrea
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

2.  NAFLD: The role of exercise in treating NAFLD.

Authors:  Elena Reynoso; Joel E Lavine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

Review 3.  Exercising the hepatobiliary-gut axis. The impact of physical activity performance.

Authors:  Emilio Molina-Molina; Raquel Lunardi Baccetto; David Q-H Wang; Ornella de Bari; Marcin Krawczyk; Piero Portincasa
Journal:  Eur J Clin Invest       Date:  2018-06-14       Impact factor: 4.686

Review 4.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?

Authors:  Nicolas Lanthier
Journal:  World J Hepatol       Date:  2015-09-08

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

10.  High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans.

Authors:  Gordon P Watt; Miryoung Lee; Jen-Jung Pan; Michael B Fallon; Rohit Loomba; Laura Beretta; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-11       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.